It was five years ago that Jeff Marrazzo, CEO of Spark Therapeutics, first stood in front of a crowd at the J.P. Morgan Healthcare Conference to outline his company's path forward. Fast forward to today, and the biotech is now a year removed from securing the first ever U.S. approval of a gene therapy for an inherited disease.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,